John Johnson
Executive Chairman, Director at Applied Therapeutics, Inc. (APLT) since December 2024
John Johnson has filed 38 insider reports with the SEC since April 2021, as director at Axogen, Inc. (AXGN), director at Xeris Biopharma Holdings, Inc. (XERS) and director at Verastem, Inc. (VSTM) and at 2 more companies. In the last 12 months John Johnson sold $2.94M of stock on the open market. The latest filing, on June 26, 2026, reports grant or award at Axogen, Inc. (AXGN).
- Filings
- 38
- Companies
- 5
- Bought on market
- None
- Sold on market
- $3.77M
Companies where John Johnson is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Directorsince July 2021 | 14,150 | $1.91M | $55.93 | Jun 26, 2026 | |||
| Director | 707,276 | $1.85M | $16.66 | Jun 5, 2026 | |||
| Director | 52,666 | $8.18 | May 26, 2026 | ||||
| Executive Chairman, Directorsince December 2024 | 500,000 | Dec 21, 2024 | |||||
| Officer, Director | 0 | Oct 6, 2021 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Jun 24, 2026AXGNSEC Form 4 filed by Director Johnson JohnForm 4Grant or award
- Jun 19, 2026AXGNDirector Johnson John converted options into 14,150 sharesForm 4Exercise or conversion of a derivative
- Jun 4, 2026-$91.4KXERSDirector Johnson John sold $91,422 worth of shares (15,000 units at $6.09) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 1% to 707,276 unitsForm 4Grant or awardOpen-market sale10b5-1 plan
- Jun 4, 2026~$88.4KXERSJohn Johnson plans to sell 15,000 shares (~$88.4K)Form 144Planned sale10b5-1 plan
- May 21, 2026VSTMDirector Johnson John was granted 36,000 shares, increasing direct ownership by 216% to 52,666 unitsForm 4Grant or award
- May 7, 2026-$478KAXGNDirector Johnson John sold $477,968 worth of shares (11,050 units at $43.26) and exercised 11,050 shares at a strike of $7.04Form 4Exercise or conversion of a derivativeOpen-market sale
- Dec 19, 2025~$977KXERSJohn Johnson plans to sell 135,402 shares (~$977K)Form 144Planned sale
- Dec 19, 2025-$977KXERSDirector Johnson John sold $977,019 worth of shares (135,400 units at $7.22), decreasing direct ownership by 16% to 698,083 unitsForm 4Open-market sale
- Dec 9, 2025-$1.39MAXGNDirector Johnson John sold $1,390,393 worth of shares (45,379 units at $30.64) and exercised 20,436 shares at a strike of $6.30, closing all direct ownership in the companyForm 4Exercise or conversion of a derivativeOpen-market sale
- Aug 13, 2025-$786KXERSDirector Johnson John sold $786,459 worth of shares (107,500 units at $7.32), decreasing direct ownership by 11% to 833,483 unitsForm 4Open-market sale
- Aug 13, 2025~$786KXERSJohn Johnson plans to sell 107,500 shares (~$786K)Form 144Planned sale
- Jun 19, 2025AXGNSEC Form 4 filed by Director Johnson JohnForm 4Grant or award
- Jun 9, 2025-$43.2KAXGNDirector Johnson John sold $43,215 worth of shares (4,073 units at $10.61), decreasing direct ownership by 14% to 24,943 unitsForm 4Open-market sale
- Jun 4, 2025XERSDirector Johnson John was granted 50,000 shares, increasing direct ownership by 6% to 940,983 unitsForm 4Grant or award
- May 22, 2025VSTMDirector Johnson John was granted 8,333 shares, increasing direct ownership by 100% to 16,666 unitsForm 4Grant or award
- Dec 19, 2024APLTExecutive Chairman Johnson John was granted 500,000 sharesForm 4Grant or award
- Dec 19, 2024APLTJohn Johnson became an insiderForm 3New insider
- Sep 1, 2024AXGNDirector Johnson John converted options into 11,904 shares, increasing direct ownership by 70% to 29,016 unitsForm 4Exercise or conversion of a derivative
- Jun 18, 2024VSTMDirector Johnson John was granted 8,333 sharesForm 4Grant or award
- Jun 6, 2024AXGNDirector Johnson John was granted 10,653 shares, increasing direct ownership by 165% to 17,112 unitsForm 4Grant or award
- Jun 5, 2024XERSJohnson John was granted 50,000 shares, increasing direct ownership by 6% to 890,983 unitsForm 4Grant or award
- Mar 15, 2024XERSJohnson John acquired 89,571 shares, increasing direct ownership by 12% to 840,983 unitsForm 4Other acquisition or disposition
- Mar 18, 2024XERSJohnson John exercised 215,600 shares at a strike of $1.99, increasing direct ownership by 40% to 751,412 unitsForm 4Exercise or conversion of a derivative
- Mar 11, 2024VSTMSEC Form 4 filed by Johnson JohnForm 4Grant or awardSale back to the company
- Sep 1, 2023AXGNSEC Form 4 filed by Johnson JohnForm 4Grant or award
- Jun 7, 2023XERSSEC Form 4 filed by Johnson JohnForm 4Grant or award
- Jun 1, 2023AXGNSEC Form 4 filed by Johnson JohnForm 4Exercise or conversion of a derivative
- May 15, 2023VSTMSEC Form 4 filed by Johnson JohnForm 4Grant or award
- May 12, 2022VSTMSEC Form 4 filed by Johnson John (Amendment)Form 4Grant or award
- Jun 22, 2022VSTMSEC Form 4 filed by Johnson JohnForm 4Grant or award
- Jun 8, 2022XERSSEC Form 4: Johnson John was granted 15,000 shares, increasing direct ownership by 3% to 493,312 unitsForm 4Grant or award
- Jun 1, 2022AXGNSEC Form 4 filed by Johnson JohnForm 4Grant or award
- Oct 5, 2021SBBPSEC Form 4: Johnson John returned 610,092 units of Ordinary Shares to the company, closing all direct ownership in the companyForm 4Sale back to the company
- Oct 1, 2021SBBPSEC Form 4: Johnson John covered exercise/tax liability with 334,868 units of Ordinary Shares, decreasing direct ownership by 35% to 610,092 unitsForm 4Shares withheld for taxes or exercise price
- Jul 19, 2021AXGNSEC Form 4 filed by JOHNSON JOHNForm 4Grant or award
- Jul 19, 2021AXGNSEC Form 3 filed by JOHNSON JOHNForm 3New insider
- Jun 28, 2021VSTMSEC Form 4 filed by JOHNSON JOHNForm 4Grant or award
- Apr 8, 2021SBBPSEC Form 4: John Johnson disposed of $46,431 worth of Ordinary Shares (17,325 units at $2.68), decreasing direct ownership by 2% to 995,827 unitsForm 4Shares withheld for taxes or exercise price
Also sits on boards with
Officers and directors who share two or more companies with John Johnson.
Compare John Johnson with
- John Johnson vs Garheng Kong2 shared
- John Johnson vs Jeffrey W Sherman2 shared
- John Johnson vs Kevin McCulloch1 shared
- John Johnson vs Dan Paterson1 shared
- John Johnson vs Steven Pieper1 shared
- John Johnson vs Beth Hecht1 shared
Other insiders at the same companies
- Kevin McCullochXERS
- Dan PatersonVSTM
- Steven PieperXERS
- Beth HechtXERS
- Menassie TaddeseXERS
- Daniel CalkinsVSTM
- Joseph A. TyndallAXGN
- John Patrick Shannon JrXERS
- Marc A BeganAXGN
- Amy McBride WendellAXGN
- Kathy Johnson WeilerAXGN
- Robert E. GagnonVSTM
- Nerissa KreherXERS
- Burke William P. Mr.AXGN
- Paul ThomasAXGN
- Alan M LevineAXGN
Questions about John Johnson
- What is John Johnson's role at Applied Therapeutics, Inc.?
- John Johnson reports to the SEC as executive Chairman and director at Applied Therapeutics, Inc. (APLT), according to the latest filing on December 21, 2024. John Johnson has also filed as director at Axogen, Inc. (AXGN), director at Xeris Biopharma Holdings, Inc. (XERS), director at Verastem, Inc. (VSTM) and officer and director at Strongbridge Biopharma plc (SBBP).
- How many shares does John Johnson own?
- After the latest filing that states it, John Johnson directly owned 14,150 shares of Axogen, Inc. (AXGN), 707,276 shares of Xeris Biopharma Holdings, Inc. (XERS), 52,666 shares of Verastem, Inc. (VSTM) and 500,000 shares of Applied Therapeutics, Inc. (APLT). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has John Johnson bought or sold stock recently?
- The most recent open-market sale was on June 4, 2026: sold 15,000 shares of Xeris Biopharma Holdings, Inc. (XERS) for $91.4K at an average of $6.09.
- How do I get alerts when John Johnson files?
- Follow John Johnson on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by John Johnson (SEC CIK 0001410781). Totals count each trade once, skipping amendments whose original is on file, from Apr 9, 2021 on. View on SEC EDGAR